Abstract Recent studies have revealed increasing rates of contralateral prophylactic mastectomy (CPM) among women with unilateral early stage breast cancer. This trend has raised concerns, given the lack of evidence for a survival benefit from CPM and the relatively low risk of contralateral breast cancer for most women in this setting. In this article, we review available data regarding the value of CPM, predictors, and outcomes related to CPM, and areas for future research and potential intervention.
Introduction
Rates of contralateral prophylactic mastectomy (CPM) among women treated for early stage breast cancer have increased dramatically in recent years [1] [2] [3] [4] [5] . This increase has been documented in several recent studies. Using surveillance, epidemiology, and end results (SEER) program data, Tuttle et al. [1] found that the proportion of mastectomy patients who underwent CPM increased from 4.2 % in 1998 to 11.0 % in 2003. Among DCIS patients, CPM rates rose from 6.4 % in 1998 to 18.4 % in 2005 [2] . Similarly, Yao et al. [3] reported an increase in CPM rates from 0.4 to 4.7 % between 1998 and 2007 among all women who had breast cancer surgery in an analysis of data from the National cancer data base (NCDB). This national trend has also been confirmed in smaller, single institution studies. Jones et al. [6] reported an increase in CPM rates from 6.5 % in 1999 to 16.1 % in 2007 at the James Cancer Hospital at The Ohio State University, and King et al. [7] documented an increase from 6.7 % in 1997 to 24.2 % in 2005 at Memorial Sloan-Kettering Cancer Center. Given, the availability of surveillance and alternative preventive options [8, 9] , and the lack of clear evidence of a survival benefit in most settings [4, [10] [11] [12] [13] [14] , there is a need to evaluate this trend.
Predictors of CPM
Studies have consistently identified that women who undergo CPM are predominantly non-Hispanic white, younger in age, more educated, married, and have a family history of breast or ovarian cancer [4, 7, 10, [15] [16] [17] . These women are also more likely to be of a higher socioeconomic status and be privately insured [3, 5] . While early stage cancers, larger tumors, lower tumor grade, negative lymph node status, and lobular type histology have been found to be associated with CPM, most research to date suggests that patient characteristics, such as age and education status, are stronger predictors of CPM than tumor factors [1, 3, 7] . Planned breast reconstruction and previous efforts to perform breast conserving surgery on the affected side have also been established as determinants of likelihood to undergo CPM [7] .
Increased imaging in breast cancer survivors, particularly the use of more sensitive modalities such as MRI, is another factor that has been evaluated to assess the contribution to higher rates of CPM. At present, data are conflicting in this regard. Arrington et al. [17] found no association between MRI usage and CPM among 571 patients who underwent breast cancer surgery in six Minnesota hospitals. In contrast, in a study of 177 women who underwent CPM matched with 178 women who did not, Chung et al. [12] reported that women who underwent preoperative MRI were twice as likely to choose CPM. Similarly, in a multi-institutional study of 3,608 women, Sorbero et al. [18] found that 9.2 % of women who underwent MRI opted for CPM, while only 4.7 % of patients who did not undergo MRI chose CPM. In a large, single institution study of almost 3,000 women who had mastectomy, King and colleagues [7] found that preoperative MRI with the indication for additional biopsy of the contralateral breast was associated with CPM.
There has also been consideration of the roles played by anxiety, misperceptions about the risks of contralateral disease and value of CPM, and/or inaccurate understanding about the systemic risks of the disease in the affected breast on the decision to undergo CPM [19, 20] . A recent analysis found that worry about recurrence was significantly associated with undergoing CPM rather than unilateral mastectomy or breast conserving surgery [21] . In a recent study surveying a cohort of young women regarding their decision to undergo CPM, 95 % of patients reported ''desire for peace of mind'' as an extremely or very important reason for choosing CPM [22] . These data suggest that women may opt for CPM for psychological rather than clinical indications. The fact that many women overestimate their risk of contralateral disease also suggests that misinformation might be influencing the decision to choose CPM [22, 23] .
In a study by Montgomery and colleagues [24] , women surveyed about their reasons for choosing CPM indicated that recommendation from a doctor was a main factor associated with the decision. Other important factors included apprehension about a second breast cancer diagnosis, a family history of breast cancer, and cosmetic symmetry [24] . It is important to note that there are other options for symmetry aside from CPM, such as mastopexy, augmentation, and reduction mammoplasty [25] . Some data also suggest that patients of female surgeons are more likely to undergo CPM [17] although this has not been confirmed in other studies [26] . Issues related to surveillance of the unaffected breast, having a multi-centric primary tumor, and having a tumor that was originally missed on mammography have also all been found to be associated with CPM [15, 27] .
Decision-making, outcomes, and satisfaction with CPM
There are a number of factors that a woman and her providers should consider in the decision to undergo CPM (see Fig. 1 ). Beyond cosmetic and emotional concerns as noted above, women should ideally have an understanding of the risk of developing contralateral breast cancer (CBC) and the efficacy of the procedure in preventing a contralateral event. Consideration of the competing risk of recurrence that a woman faces, both loco-regionally and systemically, from the breast cancer she has already developed is necessary. Understanding the risk of the procedure itself from a medical and psychosocial standpoint is also essential. For the average breast cancer survivor, the risk of developing a second primary tumor in the contralateral breast is low: 0.5-1 % per year over the first 5 years following diagnosis [28] . Population based data from Sweden demonstrated a lifetime cumulative risk of 13.3 % for women under 50-year-old at first diagnosis and 3.5 % for women older than 50 [29] . Because of the relatively low likelihood of developing CBC, the efficacy of CPM is put under greater scrutiny. While CPM is associated with a 90-97 % risk reduction of CBC [1, 10] for most women, this corresponds, on average, to an absolute risk reduction of 2.0 %. Further, the competing risk of metastasis from a history of having had primary breast cancer needs be considered in the balance and is generally far greater than the risk of a CBC.
Less controversy surrounds the decision to undergo CPM for women with markedly increased risk of contralateral disease including those with a potential hereditary predisposition to breast cancer, known BRCA1 or BRCA2 carriers or rare hereditary breast-cancer predisposing syndromes, or history of therapeutic chest irradiation. Women with a personal and strong family history of breast cancer have a 35 % risk of developing CBC within 16 years of initial diagnosis [30] . Similarly, women who are known BRCA1 or BRCA2 carriers have a 20 [31] and 12 % risk [32] , respectively, of developing CBC within 5 years of initial diagnosis. In pre-menopausal women, the use of CPM can reduce the risk of CBC by 94.4 % and in post-menopausal women by 96.0 % [33] . However, even in this setting Graves et al. [34] reported in 2007 that only 18 % of women with unilateral breast cancer elected to undergo CPM after testing positive for a BRCA mutation. Despite the potential risk reduction benefits for BRCA1 and BRCA2 carriers, Arrington and colleagues [35] found that only 7.9 % of CPM patients underwent BRCA testing prior to surgery. King et al. [7] reported that 29 % of patients undergoing CPM had had genetic testing, with a mutation rate of 31 % among those tested. These studies suggest that while the risk of developing CBC is considerably higher for women who are mutation carriers, the recent rise in use of CPM cannot be attributed primarily to these choices among these high risk women. In fact, in a recent SEER analysis, 70 % of women who had CPM did not appear to be at an elevated risk of developing cancer in their unaffected breast [36] .
While there is little dispute about the risk reduction offered by CPM, the gold standard for most cancer treatments is whether it provides a survival benefit. Data are mixed with regard to the benefits of CPM with the majority of studies suggesting no survival advantage (see Table 1 ). Herrinton et al. [10] reported a 43 and 40 % reduced risk of breast cancer and all-cause mortality, respectively, associated with CPM. More recently, Bedrosian et al. [11] reported better 5-years survival associated with CPM in patients younger than 50 with early stage, ER-negative disease. In a study by Peralta et al. [4] CPM was associated with better disease-free survival, however there was no statistically significant difference in overall survival between women who had CPM and those who did not; similarly, there was no difference in survival between women who had CPM and those undergoing unilateral mastectomy in a study by Chung et al. [12] . A recent systematic review also concluded that CPM does not offer a survival benefit [14] . Among high risk women, some recent studies suggest a survival benefit [37, 38] ; however, this has not been found in other studies [13] . Because there have been no randomized trials of CPM, consideration of the biases inherent in these studies is warranted. Women who are chosen are counseled to undergo CPM may be healthier than non-CPM patients, with less comorbidity and less aggressive primary disease.
It is important to note that studies have demonstrated that satisfaction with CPM is generally high among women who have had the procedure. Geiger et al. [39] found 86.5 % of CPM patients were satisfied with their decision to undergo CPM. Nekhlyudov et al. [16] reported that women who reported active roles in their decision-making process (defined as the woman deciding alone or deciding after hearing her physician's opinion) were twice as likely to be satisfied with their decision to undergo CPM compared to women who reported passive roles. Similarly, Montgomery et al. [24] found that only 6 % of CPM patients reported regrets. In this study, the main issues of regret among women who underwent CPM were poor cosmetic outcomes (from either CPM or reconstruction), lessened feelings of sexuality, and a lack of knowledge about different modes of screening for the other breast [24] . Not surprisingly, however, in a study by Rolnick et al. [40] , only 58 % of women who had been diagnosed with breast cancer and underwent CPM wished they had been given more information prior to their surgery in contrast to 79 % of women without a history of breast cancer undergoing bilateral prophylactic mastectomy who wished they had been given more information. Further, satisfaction with CPM has been found to be high among women with both a family and personal history of breast cancer [41] .
Data are mixed regarding the impact of CPM on psychological outcomes. While, Unokovych et al. [42] found that CPM was not associated with any negative long-term psychological outcomes; Tuli et al. [43] reported a high prevalence of depression among women who had CPM. Medical outcomes should also be considered. One study detected higher rates of adverse events following surgery, including higher post-surgical infection rates and greater likelihood of additional surgical intervention among CPM patients, compared to unilateral mastectomy patients [44] .
Limitations and future directions
Despite the recent surge in research about the rates and efficacy of contralateral prophylactic mastectomy, the data available remain limited. Most studies reviewed were retrospective database or medical record reviews. While these studies have provided valuable information about the risk reduction associated with CPM, it is difficult to discern what truly drives women to undergo CPM without prospective data. Research to date has shown that there are many factors associated with CPM and future research is warranted to see if and how such factors influence the decision-making processes. There are also limitations with many of the larger database studies based on patient information collected many decades earlier. Older, less effective treatments led to a higher rate of metastasis and poorer survival, as well as lower rates of CBC. Therapeutic advances for current breast cancer patients has improved survival [45] ; however, this will also likely result in an increased incidence of CBC in an aging survivor population.
Additional data is needed to better understand the role of cost in relation to the decision to undergo CPM. Interestingly, a recent decision analysis [46] found CPM to be more cost-effective when compared to regular surveillance among women under the age of 70. There is also a need for prospective data about why women choose CPM and how this choice affects both health and psychosocial outcomes. Data collected both prior to and after surgery would allow for the assessment of how patients' thoughts and emotions change throughout their treatment. For example, if CPM resulted in reduced levels of anxiety in women, this could potentially change how providers counsel patients about this topic. Similarly, prospective data related to satisfaction with cosmetic outcome and symmetry is also needed. Without prospective data, it is difficult to accurately measure any changes that a woman experiences throughout the course of her treatment and into the survivorship period.
It would also be valuable to examine patients of different aged cohorts. Young women undergo CPM at higher rates than older patients [6, 7, 10, [15] [16] [17] 20] . Younger patients are a unique population who often have younger children or are still dating, and may still be in the formative years of their career. During this phase in life, younger women might feel more driven to have their opposite breast removed as a preventive measure. Body image issues may be more pertinent to younger women, and therefore they might be more likely to choose CPM for cosmetic reasons. Furthermore, while younger women are often diagnosed with more advanced disease [47] they generally have few co-morbidities and are typically good surgical candidates. Importantly, younger patients are also more likely to suffer from post-mastectomy pain syndrome than their older counterparts [48] .
Finally, it is likely that some women who undergo CPM have misperceptions about the actual risks and values of the surgery. Improved education and counseling is likely to help and decision aids may be particularly useful in this setting to assure that patients are making choices that are consistent with their preferences and values and should be studied [49] [50] [51] . For some women, when weighing all of the pros and cons, CPM may be the right choice. In order for caregivers to provide quality care to their patients and inform this decision, and for patients to achieve optimal medical and psychosocial outcomes, further research to determine both the short and long-term risks and benefits associated with CPM is warranted.
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